Results
Overall, MERIT-HF demonstrated a hazard ratio of 0.66 for total mortality and 0.81 for mortality plus all-cause hospitalization. The hazard ratio of the first secondary end point of mortality plus hospitalization for heart failure was 0.69. The results were remarkably consistent for both primary outcomes and the first secondary outcome across all predefined subgroups as well as for nearly all post hoc subgroups. The results of the post hoc US subgroup showed a mortality hazard ratio of 1.05. However, the US results regarding both the second primary combined outcome of total mortality plus all-cause hospitalization and of the first secondary combined outcome of total mortality plus heart failure hospitalization were in concordance with the overall results of MERIT-HF. Tests of country by treatment interaction (14 countries) revealed a nonsignificant P value of .22 for total mortality. The mortality hazard ratio for US patients in New York Heart Association (NYHA) class III/IV was 0.80, and it was 2.24 for patients in NYHA class II, which is not consistent with causality by biologic gradient. We have not been able to identify any confounding factor in baseline characteristics, baseline treatment, or treatment during follow-up that could account for any treatment by country interaction. Thus we attribute the US subgroup mortality hazard ratio to be due to chance.
Conclusions Just as we must be extremely cautious in overinterpreting positive effects in subgroups, even those that are predefined, we must also be cautious in focusing on subgroups with an apparent neutral or negative trend. We should examine subgroups to obtain a general sense of consistency, which is clearly the case in MERIT-HF. We should expect some variation of the treatment effect around the overall estimate as we examine a large number of subgroups because of small sample size in subgroups and chance. Thus the best estimate of the treatment effect on total mortality for any subgroup is the estimate of the hazard ratio for the overall trial. (Am Heart J 2001;142:502-11.)
Also, the analysis of the US Carvedilol Program 7 indicated a favorable effect on these end points. In this article we examine the consistency of β-blocker effect across various predefined risk groups as well as post hoc subgroups in one of these trials, MERIT-HF. MERIT-HF was a large-scale randomized placebo-controlled survival trial designed to investigate whether metoprolol succinate controlled/extended release (CR/XL) once daily added to optimum standard therapy lowers total mortality (first primary outcome) and the combined outcome of total mortality plus all-cause hospitalization (second primary outcome, time to first event) in patients with chronic heart failure, New York Heart Association (NYHA) class II-IV. The study was performed in 14 countries including the United States, and the overall results on 3991 patients randomized for MERIT-HF have been reported elsewhere. [1] [2] [3] [4] The International Steering Committee of MERIT-HF stopped the trial because of a highly significant reduction of total mortality in the metoprolol CR/XL group. The final results revealed 145 deaths in the metoprolol CR/XL group and 217 in the placebo group (hazard ratio of 0.66, a 34% reduction, a nominal P = .00009). 2 The results of the second primary outcome of total mortality plus all-cause hospitalization were also highly statistically significant (641 vs 767 events, hazard ratio of 0.81, a 19% reduction, nominal P = .00012). 3 Given the earlier concern about the use of β-blockers in patients with chronic heart failure, it is natural to examine the well-known risk factor subgroups to determine whether any particular subgroup is at excess risk for this treatment. However, analysis of subgroups is both compelling 8 and challenging. 9, 10 Trials are typically designed for adequate power to test the overall treatment effect, and subgroups are rarely large enough to provide definitive answers. Thus subgroup results will vary around the overall observed treatment effect because of chance and small sample size so that such analyses should focus on the "overall" consistency rather than the deviation in any particular subgroup.
In MERIT-HF, all the predefined subgroups showed a remarkable consistency of treatment benefit on both the 2 primary outcomes, total mortality, and total mortality plus all-cause hospitalization as well as the first secondary outcome, total mortality plus hospitalization for heart failure. Many other post hoc subgroup analyses were also done and these were also nearly all consistent. However, one such subgroup of US patients did not show a reduction in total mortality but the other 2 outcomes in the United States were consistent with the overall trial results. We have examined this anomaly of a treatment by country interaction and present a discussion of those results. The implications of focusing on a particular country subgroup result for international trials are also discussed.
Methods
A total of 3991 patients with symptomatic chronic heart failure and decreased ejection fraction stabilized on standard treatment were randomized at 313 investigational sites in Belgium, the Czech Republic, Denmark, Finland, Germany, Hungary, Iceland, the Netherlands, Norway, Poland, Sweden, Switzerland, the United Kingdom, and the United States. The randomization was performed in 16 randomization regions, 3 regions in United States (northern, middle and southern states), and 1 region each for the other participating countries. For prespecified detailed description of study objectives, study patients, and study treatment and measurements see references. [1] [2] [3] An Independent Safety Committee monitored safety issues during the study. The stopping rule for efficacy was based on the total number of expected deaths, analyzed on an intention-to-treat principle. A Peto-type boundary was used for monitoring a positive trend. The second preplanned interim analysis of total mortality was based on 296 deaths reported by September 15, 1998 . The point estimate of the hazard ratio was then 0.64 (nominal P = .00015). The Independent Safety Committee recommended early closure of the study.
Data analysis plan for MERIT-HF
The MERIT-HF study had a predefined data analysis plan, which in detail defined all prespecified analyses to be performed. The analysis was by intention to treat (eg, all patients randomized). The main analyses used the log-rank test for the comparison of the 2 randomized groups and the Cox proportional hazards model to calculate relative risk and 95% confidence intervals. The data analysis plan included 1 paragraph relating to subgroup analyses to be performed. The International Steering Committee decided to do such analyses only for safety reasons. The rationale for doing analyses as stated in this data analysis plan was to explore any unfavorable outcome in prespecified subgroups [1] [2] [3] and not to look for efficacy in subgroups because the study was only powered for prespecified efficacy analysis in all patients randomized. The prespecified safety analyses in subgroups were to be performed for the 2 primary end points and the first secondary end point, but only if a total of 180 events or more in the 2 randomization groups combined were observed in the subgroup. One hundred eighty events would give a reasonable power to detect an unfavorable outcome. [1] [2] [3] The results of these primary safety analyses have been published. 2, 3 The International Steering Committee of MERIT-HF also decided to provide data on complementary subgroups having <180 events, for example, giving data for women having <180 deaths (64 deaths) when giving data for men with >180 deaths.
Testing for the presence of interactions
After discussions with the Food and Drug Administration (FDA), it was decided to perform interaction by country analyses. This was accomplished by consulting biostatisticians who were independent of the sponsor.
In a study in which patients were recruited in 14 different countries, the examination of country-specific effects is made imprecise because of chance variation. The most appropriate way of proceeding is to assess the extent of country by treatment interactions. 11 Of particular interest were significant qualitative interactions, not just quantitative (ie, different magnitude) interactions. Detecting significant departures from the overall effect among any of the many participating countries involves multiple testing. Because of the multiplicity involved, a joint test to detect any interaction among all the countries/regions was used. To have estimable interaction effects for the analysis of mortality, it was necessary to group 2 countries (Finland and Switzerland) together with other countries because the number of deaths was 0 in the metoprolol CR/XL group. Thus mortality observations from Denmark and Finland and from the Netherlands and Switzerland, respectively, were each combined into 1 randomization region. The outcome of the interaction analysis did not change if other groupings were made. In one analysis the 3 US randomization regions were also grouped together.
The end points chosen for the interaction analyses were the 2 primary end points. Figure 1 gives absolute numbers, point estimates of the hazard ratios, and 95% confidence intervals (for combined end point time to first event) for total mortality, total mortality plus all-cause hospitalization, and total mortality plus hospitalization for worsening heart failure from prespecified analyses in predefined subgroups according to baseline characteristics. Table I presents the number of patients randomized by country and overall and also some baseline characteristics per country in the 2 randomization groups. Table II presents use of concomitant treatment for heart failure by country and overall. Figure 2 presents absolute numbers, point estimates of the hazard ratio, and 95% confidence intervals for the 2 primary end points and the first secondary end point in the 14 participating countries and for the study
Results

Figure 1
Absolute numbers, point estimates of the hazard ratios, and 95% confidence intervals (for combined end point time to first event) for total mortality, total mortality plus all-cause hospitalization, and total mortality plus hospitalization for worsening heart failure from prespecified analyses in predefined subgroups according to baseline characteristics. Filled squares, Subgroups with a total of 180 events or more; open squares, subgroups with a total of <180 events (low power). Meto, Metoprolol; CHF, chronic heart failure; EF, ejection fraction; MI, myocardial infarction; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure. as a whole. Test of randomization region by treatment interaction (n = 16) revealed a P value of .32 for total mortality and .53 for the combined end point of all-cause mortality plus all-cause hospitalization (time to first event). Test of country by treatment interaction (n = 14) revealed a P value of .22 for total mortality and .70 for the combined end point of total mortality plus all-cause hospitalization. Figure 3 gives the same data separately for patients in NYHA class III/IV at baseline (upper panel) and NYHA class II at baseline (lower panel). Interestingly, the data for the US subgroup revealed a point estimate below 1.0 for total mortality in class III/IV patients and above 1.0 in class II patients. Analysis of cause-specific mortality in the US subgroup in NYHA class II revealed a low number of events in each category in both treatment groups with no indication of causal association of deaths with metoprolol CR/XL therapy (Table III) .
Comment
The overall results from MERIT-HF demonstrated that metoprolol CR/XL given once daily in addition to conventional therapy in patients with chronic heart failure improved survival, reduced the need for hospital admissions for worsening heart failure, and also improved symptoms and well-being. [1] [2] [3] [4] No significant increase in total mortality, in total mortality plus allcause hospitalizations (time to first event), or in total mortality plus hospitalizations for worsening heart failure (time to first event) were observed in any of the predefined subgroups analyzed for safety reasons ( Figure 1 ).
All analyses of clinical end points and other prespecified effect variables in MERIT-HF were done by intention to treat. The study protocol defined 3 categories of effect variables primary, secondary, and tertiary, which reflect the judgment of the International Steering Committee of the importance of these variables. The Committee had a very conservative approach to prespecified subgroup analyses in general to avoid the possibility of chance findings. Subgroup analyses were therefore only prespecified for safety reasons. We had not prespecified to do test of country by treatment interaction because the study, as all other earlier performed multinational survival studies, lacked power for such an analysis. However, after the expressed interest by the FDA on the mortality figures in the United States, it was decided to perform a conventional region and country by treatment interaction analysis of the mortality data. Randomization was performed within each of 16 randomization regions, 3 in the United States and one region each in the other participating countries. Post-hoc test of randomization region by treatment interaction revealed a P value of .32 for total mortality. This analysis took into account all possible country comparisons, but no correction for the prespecified safety interaction analyses was done in the analysis (multiplicity of testing, see below). If instead the United States was used as one region, the P value was .22. Because no statistically significant interaction by country was found in any analysis, it is our opinion that the most valid estimate of the survival benefit for US patients with chronic heart failure is the overall mortality results of the study.
There is no unique interaction analysis. The FDA performed a post hoc interaction analysis contrasting the United States (hazard ratio 1.05, 95% confidence interval [CI] 0.71-1.56) with all other countries combined (hazard ratio 0.55, 95% CI 0.43-0.70) and in this way found a significant quantitative interaction (P = .003). However, this analysis did not correct for multiplicity of testing (all possible country comparisons and prespecified safety analyses). In a similar analysis performed by Sir Richard Peto of the Oxford group including 13 subgroup analyses, 12 prespecified for safety reasons (see Figure 1 , ethnic group not included in Peto's analysis), and 1 post hoc (United States vs all other countries combined), none was conventionally significant when a Bonferroni correction was used to allow for the fact that 13 interaction tests were done (P = .08 for the most extreme one, which was post hoc). This correction did not take into account all possible country comparisons.
In our view the comparison of the US subgroup with all other countries combined is not a logical or valid comparison because the other countries outside the United States do not represent a homogenous group regarding background epidemiologic characteristics, social economic characteristics, or standard of care. We also doubt that these characteristics interact with β-blocker treatment. Noteworthy is that the effect of β-blocker treatment on mortality when broken down by country as expected showed a random variation around a common mean (Figures 2 and 3) , underlining the importance of looking at the overall effect when trying to estimate the true effect. Also, the mortality rate in the placebo group in the different countries showed a random variation around a common mean (Figure 4 ). Both NYHA class II and III/IV US patients showed point estimates for the combined end points of total mortality plus all-cause hospitalizations (time to first event) and of total mortality plus hospitalization for heart failure similar to the overall highly significant positive effect (Figure 3 ). Thus, with more events in a subgroup, as for the combined end points, a more accurate estimate of the overall effect can be expected.
Which ways are there to analyze and understand unexpected findings in subgroups and to gain knowledge about causality?
The well-known criteria formulated by Sir Bradford Hill can be applied because these offer a structured way to attack the problem. 12 Some of these criteria may be described as follows:
1. The rule of chance/the strength of association 2. The biologic gradient 3. Consistency (internal/external) 4. Confounding 5. Coherence/plausibility.
The rule of chance/the strength of association.
This criterion has been discussed above. The data are well in accordance with a chance finding. The P value for the treatment by country interaction analysis shows no strength of association. Belgium  52  68  38  36  13  8  15  16  Czech Republic  69  66  54  62  37  36  17  17  Denmark  84  79  115  126  16  21  16  17  Finland  85  79  134  62  60  57  19  13  Germany  48  53  83  90  28  28  13  12  Hungary  81  80  32  39  63  61  12  10  Iceland  95  91  92  89  53  50  6  8  Norway  88  90  56  60  42  34  16  17  Poland  73  68  43  36  27  28  13  15  Sweden  95  87  85  86  31  46  19  16  Switzerland  57  57  77  47  24  38  28  23  The Netherlands  60  56  54  52  30  35  14 Internal consistency. The second primary end point was the combined end point of total mortality plus allcause hospitalization (time to first event). 3 The hazard rate point estimate for the effect of metoprolol CR/XL on this end point in the United States was below 1 32  41  77  71  22  24  15  13  5  20  23  66  55  0  2  0  13  13  26  26  66  67  4  6  8  8  29  10  21  88  85  5  0  20  -0  32  31  51  50  6  7  13  14  10  17  18  57  55  1  4  13  16  4  32  36  71  42  0  0  --0  16  19  95  77  28  31  13  14  0  51  49  39  29  0  0  --10  10  11  84  85  13  11  11  20  6  19  0  78  -14  14  18  20  24  23  23  65  59  14  11  14  11  11  16  8  63  57  39  33  12  12  4  14  11  107  88  27  28  20  19  22 (Figure 2 ), thus showing a positive trend similar to the overall significant study results. This was the case also for the subgroups in NYHA class II and NYHA class III/IV, respectively (Figure 3 ). Thus the US data on the combined end points were not consistent with a neutral effect on mortality.
External consistency. As early as in 1986 the Beta Blocker Heart Attack (BHAT) trial published a positive effect of propranolol in patients after myocardial infarction with congestive heart failure. 13, 14 Another example of the consistency of a true effect of β-selective β-blockade on mortality in patients with chronic heart Figure 2 Absolute numbers, point estimates of the hazard ratios, and 95% confidence intervals (for combined end point time to first event) for total mortality, total mortality plus all-cause hospitalization, and total mortality plus hospitalization for worsening heart failure in post hoc subgroups according to country (all patients randomized). Filled squares, Subgroups with a total of 180 events or more; open squares, subgroups with a total of <180 events (low power). Meto, Metoprolol. *Two deaths from postoperative complications and three from nonsteroidal anti-inflammatory drug-induced renal failure, pneumonia, and undetermined cause, respectively. Three of 5 patients discontinued metoprolol CR/XL 181, 97, and 33 days before death, respectively. †One patient was off medication for 130 days before his death. ‡One patient was off medication for 93 days before his fatal myocardial infarction. Table III . Cause-specific mortality in the US subgroup of MERIT-HF for all patients randomized and by NYHA class III/IV and NYHA class II, respectively
Figure 3
Absolute numbers, point estimates of the hazard ratios and 95% confidence intervals (for combined end point time to first event) for total mortality, total mortality plus all-cause hospitalization, and total mortality plus hospitalization for worsening heart failure in post hoc subgroups according to country (top, subgroup of patients in NYHA class III/IV at baseline; bottom, subgroup of patients in NYHA class II at baseline). Filled squares, Subgroups with a total of 180 events or more; open squares, subgroups with a total of <180 events (low power). Meto, Metoprolol; Plac, placebo.
failure is the results from CIBIS-II. 5 The CIBIS-II study demonstrated that bisoprolol had effects on mortality and hospitalizations that were almost identical to those observed in the MERIT-HF study. Other examples are the carvedilol trials in United States 7 and the recent COPERNICUS trial, 6 which was stopped because of a positive effect on mortality nearly identical to that in the MERIT-HF study. The COPERNICUS trial randomized patients in NYHA class III/IV with an ejection fraction below 0.25 (mean 0.20 at baseline), and results showed a 35% reduction in total mortality with carvedilol (placebo mortality 18.5%). 6 The results from a subgroup of MERIT-HF in NYHA III/IV and with an ejection fraction below 0.25 (mean 0.19 at baseline) are consistent with these results (39% reduction in total mortality with metoprolol CR/XL and 19.1% placebo mortality). 15 Confounding. We have not been able to identify any confounding factor in baseline characteristics, baseline treatment, or treatment during follow-up that could come in as a factor of importance for causality. A post hoc interaction analysis of angiotensin-converting enzyme (ACE) inhibitor use showed very similar point estimates for the hazard ratio in patients not on con Coherence/plausibility. The remarkable consistency of results of MERIT-HF across known predefined risk groups provides a great deal of assurance that β-blockers, metoprolol CR/XL in particular, are generally effective. Results of the 2 primary outcomes are also quite consistent across countries. The US subgroup is consistent for 2 of 3 main outcome measures and is consistent even within total mortality for NYHA class III/IV. Given the large number of subgroups examined, the smaller sample size in any particular subgroup, and no apparent differences in either baseline risk factors or background therapy, the most likely explanation for the particular US subgroup result is chance.
Conclusions and implications
We have carefully examined the 2 primary outcomes and the first secondary outcome over a large number of subgroups, both those predefined and several defined post hoc. We find remarkable consistency across all the predefined risk subgroups in all the 3 outcomes. Even for subgroups by country, there is an overall consistency across the 3 outcomes with small variation around the overall mean treatment effect. Within the US subgroup, there is consistency except for the NYHA class II patients, which has a very small sample size, a very low placebo mortality rate, and an imprecise estimate of treatment effect (Figure 3 , lower panel, and Figure 4) . After careful analysis, we cannot find any imbalance in baseline risk factors or background therapy that could account for this discrepancy.
Figure 4
Risk in placebo groups defined as number of deaths reported divided by patient-years of follow-up in the 14 participating countries and in the whole study group. Number within brackets gives total number of deaths in the placebo group. Top, All NYHA classes; middle, NYHA classes III/IV; bottom, NYHA class II.
In general, we believe that the best estimate of treatment effect for any given subgroup is still the overall treatment effect. The examination of subgroups should be on a qualitative basis and not by a quantitative estimate of treatment effect. Subgroups are almost always too small to provide definitive or reliable quantitative answers and are vulnerable to chance results, albeit positive, neutral, or negative. Given the analysis of the MERIT-HF, we find the results to be remarkably consistent across risk factors and even across countries. The one apparent anomaly in the US mortality result is not so inconsistent with the overall treatment effect and with the level of variation one could expect.
If the interpretation of clinical trial results focuses too heavily on subgroups, then trials must be designed to provide definitive answers for that subgroup. Thus there are no short cuts. If there really is a well-based hypothesis that any specific and important risk or cultural subgroup would qualitatively interact with the treatment under evaluation, then an appropriately powered trial must, if possible, be performed just for that subgroup. It would be very challenging to design trials such as MERIT-HF to have definitive outcomes in any risk group and practically impossible to do so for any specific country. For that reason, most trials are now multinational so that recruitment can be achieved in a practical time frame. In particular, if trials had to be powered for the US and non-US subgroups, we would essentially be promoting 2 studies, a US trial and a non-US trial. Data and safety monitoring committees would be in a dilemma as to how to terminate one country subgroup and not the other. The paradigm that we have used in other areas is to use the overall treatment effect to guide our interpretation and clinical practice. As an example, the Scandivavial Simvastatin Survival Study (4S) 16 was conducted totally in Scandinavian countries but led to a global change in the treatment of hypercholesterolemia, including in the United States. Another similar example is the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS I) trial with severe NYHA class IV heart failure. 17 In summary MERIT-HF, CIBIS-II, and COPERNICUS have, taken together, demonstrated overwhelmingly significant positive effects on total mortality as well as on total mortality plus all-cause hospitalization in patients with heart failure and decreased ejection fraction. National and international guidelines are now being changed to include the β-blockers metoprolol CR/XL, bisoprolol, and carvedilol for routine treatment in patients with heart failure. We believe that the best estimate of treatment effect for any particular subgroup, including country, should be the overall effect observed in these trials, and our future trial design and evaluation should be based on that paradigm.
